BioLineRx Ltd.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx Ltd. (NASDAQ:BLRX) reported first-quarter 2026 financial results on Wednesday, shortly after announcing that the first patient had been dosed in its Phase 1/2a clinical study evaluating GLIX1 for the treatment of glioblastoma.
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent. This is a 87.06 percent increase over sales of $255.000 thousand
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing
BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.
GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally administered GLIX1
The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase
Despite a significant revenue drop, BioLine Rx Ltd (BLRX) focuses on innovative treatments and maintains a strong cash position to drive future growth.
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.54) by 37.04 percent. The company reported quarterly sales of $194.000 thousand which missed the
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call March 23, 2026 8:30 AM EDTCompany ParticipantsIrina Koffler - Managing DirectorPhilip Serlin - Chief Executive...
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent. This is a 98.35 percent decrease over sales of $11.749 million
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
https://ir.biolinerx.com/static-files/e6f7cf56-4605-44e6-8ed9-f0738b67b983
BioLine Rx Ltd (BLRX) reports reduced net loss and strategic developments in cancer treatment, bolstered by a strong cash position.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.32 | — | — |
| 2026-05-27 | -1.04 | — | +100.00% |
| 2026-03-23 | -0.77 | — | +100.00% |
| 2025-11-24 | -0.54 | — | +100.00% |
| 2025-08-14 | -0.53 | — | +100.00% |
| 2025-05-27 | -1.06 | — | +100.00% |
| 2024-11-25 | -4.40 | — | +100.00% |
| 2024-08-15 | -5.60 | — | +100.00% |
| 2024-05-28 | -11.60 | — | +100.00% |
| 2024-03-26 | -8.80 | -3.58 | +59.36% |
| 2023-11-20 | -8.40 | -12.00 | -42.86% |
| 2023-08-30 | -6.80 | -12.00 | -76.47% |
| 2023-05-24 | -5.60 | -6.00 | -7.14% |
| 2023-03-22 | -5.40 | — | +100.00% |
| 2022-11-15 | -4.53 | -6.00 | -32.35% |
| 2022-08-16 | -5.20 | -6.00 | -15.38% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BLRX | +32.17% | +34.52% | +36.46% | -28.00% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +29.20% | +39.16% | +39.91% | -40.69% |